PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification

Tabernero, J.Bekaii-Saab, T.Aguilera, M. SafontCubillo, A.Garcia-Carbonero, R.Limon, L.Rodriguez-Salas, N.Tournigand, C.Borg, C.Raghav, K.Finley, G.Strickler, J.Beier, F.Salim, S.Esser, R.Liu, E.Adrian, S.Lopez-Lopez, C.2025-01-072025-01-072021-07-030923-7534https://hdl.handle.net/10668/27224enPERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplificationconference outputopen access10.1016/j.annonc.2021.05.1661569-8041http://www.annalsofoncology.org/article/S0923753421013557/pdf670004200111